Last reviewed · How we verify
Genexine, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
5 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| NESP | NESP | phase 3 | erythropoiesis-stimulating agent | erythropoietin receptor | Nephrology |
Therapeutic area mix
- Diabetes · 1
- Nephrology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American Regent, Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Hoffmann-La Roche · 1 shared drug class
- Mathew S. Maurer · 1 shared drug class
- National Taiwan University Hospital · 1 shared drug class
- Sandoz · 1 shared drug class
- Sunnybrook Health Sciences Centre · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Genexine, Inc.:
- Genexine, Inc. pipeline updates — RSS
- Genexine, Inc. pipeline updates — Atom
- Genexine, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Genexine, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genexine-inc. Accessed 2026-06-10.